Levetiracetam Hospira
levetiracetam
levetiracetam
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What Levetiracetam Hospira is and what it is used for
What you need to know before you are given Levetiracetam Hospira
How Levetiracetam Hospira is given
Possible side effects
How to store Levetiracetam Hospira
Contents of the pack and other information
Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy). Levetiracetam Hospira is used:
on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits.
as an add-on to other antiepileptic medicines to treat:
partial onset seizures with or without generalisation in adults, adolescents and children from 4 years of age.
myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.
primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
Levetiracetam Hospira concentrate for solution for infusion is an alternative for patients when administration of the antiepileptic levetiracetam medicine by mouth is temporarily not feasible.
If you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6).
Talk to your doctor before you are given Levetiracetam Hospira
If you suffer from kidney problems, follow your doctor’s instructions. He/she may decide if your dose should be adjusted.
If you notice any slowdown in the growth or unexpected puberty development of your child, please contact your doctor.
A small number of people being treated with anti-epileptics such as Levetiracetam Hospira have had thoughts of harming or killing themselves. If you have any symptoms of depression and/or suicidal ideation, please contact your doctor.
If you have a family or medical history of irregular heart rhythm (visible on an electrocardiogram), or if you have a disease and/or take a treatment that make(s) you prone to heartbeat irregularities or salt imbalances.
Tell your doctor or pharmacist if any of the following side effects gets serious or last longer than a few days:
Abnormal thoughts, feeling irritable or reacting more aggressively than usually, or if you or your family and friends notice important changes in mood or behaviour.
Aggravation of epilepsy
Your seizures may rarely become worse or happen more often, mainly during the first month after the start of the treatment or increase of the dose. If you experience any of these new symptoms while taking Levetiracetam Hospira, see a doctor as soon as possible.
Levetiracetam Hospira is not indicated in children and adolescents below 16 years on its own (monotherapy).
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Do not take macrogol (a drug used as laxative) for one hour before and one hour after taking levetiracetam as this may results in a reduction of its effect.
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Levetiracetam can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor. You should not stop your treatment without discussing this with your doctor. A risk of birth defects for your unborn child cannot be completely excluded. Breast-feeding is not recommended during treatment.
Levetiracetam Hospira may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. This is more likely at the beginning of treatment or after an increase in the dose. You should not drive or use machines until it is established that your ability to perform such activities is not affected.
One maximum single dose of Levetiracetam Hospira concentrate contains 57 mg of sodium (19 mg of sodium per vial) equivalent to 2.85% of the recommended maximum daily dietary intake of sodium for an adult. This should be taken into consideration if you are on a controlled sodium diet.
A doctor or a nurse will administer you Levetiracetam Hospira as an intravenous infusion. Levetiracetam Hospira must be administered twice a day, once in the morning and once in the evening, at about the same time each day.
The intravenous formulation is an alternative to your oral administration. You can switch from the film-coated tablets or from the oral solution to the intravenous formulation or reverse directly without dose adaptation. Your total daily dose and frequency of administration remain identical.
Adjunctive therapy and monotherapy (from 16 years of age)
Recommended dose: between 1,000 mg and 3,000 mg each day.
When you first start taking Levetiracetam Hospira, your doctor will prescribe you a lower dose for 2 weeks before giving you the lowest daily dose.
Recommended dose: between 20 mg per kg bodyweight and 60 mg per kg bodyweight each day.
Levetiracetam Hospira is for intravenous use.
The recommended dose must be diluted in at least 100 ml of a compatible diluent and infused over 15-minutes.
For doctors and nurses, more detailed direction for the proper use of Levetiracetam Hospira is provided in section 6.
There is no experience with administration of intravenous levetiracetam for a longer period than 4 days.
If stopping treatment, as with other antiepileptic medicines, Levetiracetam Hospira should be discontinued gradually to avoid an increase of seizures. Should your doctor decide to stop your Levetiracetam Hospira treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Hospira.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction
swelling of the face, lips, tongue and throat (Quincke’s oedema)
flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS])
symptoms such as low urine volume, tiredness, nausea, vomiting, confusion and swelling in the legs, ankles or feet, as this may be a sign of sudden decrease of kidney function
a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme)
a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome)
a more severe form of rash causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis)
signs of serious mental changes or if someone around you notices signs of confusion, somnolence (sleepiness), amnesia (loss of memory), memory impairment (forgetfulness), abnormal behaviour or other neurological signs including involuntary or uncontrolled movements. These could be symptoms of an encephalopathy.
The most frequently reported adverse reactions were nasopharyngitis, somnolence (sleepiness), headache, fatigue and dizziness. At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. These effects should however decrease over time.
nasopharyngitis;
somnolence (sleepiness), headache.
anorexia (loss of appetite);
depression, hostility or aggression, anxiety, insomnia, nervousness or irritability;
convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness), lethargy (lack of energy and enthusiasm), tremor (involuntary trembling);
vertigo (sensation of rotation);
cough;
abdominal pain, diarrhoea, dyspepsia (indigestion), vomiting, nausea;
rash;
asthenia/fatigue (tiredness).
decreased number of blood platelets, decreased number of white blood cells;
weight decrease, weight increase;
suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, hallucination, anger, confusion, panic attack, emotional instability/mood swings, agitation;
amnesia (loss of memory), memory impairment (forgetfulness), abnormal coordination/ataxia (impaired coordinated movements), paraesthesia (tingling), disturbance in attention (loss of concentration);
diplopia (double vision), vision blurred;
elevated/abnormal values in a liver function test;
hair loss, eczema, pruritus;
muscle weakness, myalgia (muscle pain);
injury.
infection;
decreased number of all blood cell types;
severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke’s oedema [swelling of the face, lips, tongue and throat]);
decreased blood sodium concentration;
suicide, personality disorders (behavioural problems), thinking abnormal (slow thinking, unable to concentrate);
delirium;
encephalopathy (see sub-section “Tell your doctor immediately” for a detailed description of symptoms);
seizures may become worse or happen more often;
uncontrollable muscle spasms affecting the head, torso and limbs, difficulty in controlling movements, hyperkinesia (hyperactivity);
change of the heart rhythm (Electrocardiogram);
pancreatitis;
liver failure, hepatitis;
sudden decrease in kidney function;
skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens- Johnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis);
rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.
limp or difficulty walking;
combination of fever, muscle stiffness, unstable blood pressure and heart rate, confusion, low level of consciousness (may be signs of a disorder called neuroleptic malignant syndrome). Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.
If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the vial and carton box after EXP: The expiry date refers to the last day of the month.
This medicine does not require any special storage conditions.
The active substance is called levetiracetam. Each ml contains 100 mg of levetiracetam.
The other ingredients are: sodium acetate trihydrate, glacial acetic acid, sodium chloride, water for injections (see section 2 Levetiracetam Hospira contains sodium).
Levetiracetam Hospira concentrate for solution for infusion (sterile concentrate) is a clear, colourless solution.
Levetiracetam Hospira concentrate for solution for infusion is packed in a cardboard box containing 10 or 25 vials of 5 ml.
Not all pack sizes may be marketed.
1050 Bruxelles Belgium
Pfizer Service Company BVBA Hoge Wei 10
1930 Zaventem Belgium
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
Pfizer NV/SA
Tél/Tel: +32 (0) 2 554 62 11
Pfizer Luxembourg SARL filialas Lietuvoje Tel. + 370 52 51 4000
Пфайзер Люксембург САРЛ, Клон България Тел.: +359 2 970 4333
Pfizer NV/SA
Tél/Tel: +32 (0) 2 554 62 11
Pfizer, spol. s r.o.
Tel: +420-283-004-111
Pfizer Kft.
Tel: + 36 1 488 37 00
Pfizer ApS
Tlf: + 45 44 20 11 00
Drugsales Ltd
Tel: + 356 21 419 070/1/2
PFIZER PHARMA GmbH Tel: +49 (0)30 550055-51000
Pfizer bv
Tel: +31 (0)800 63 34 636
Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7500
Pfizer AS
Tlf: +47 67 52 61 00
Pfizer ΕΛΛΑΣ A.E. Τηλ.: +30 210 6785 800
Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0
Pfizer, S.L.
Tel: +34 91 490 99 00
Pfizer Polska Sp. z o.o. Tel: +48 22 335 61 00
Pfizer
Tél: + 33 (0)1 58 07 34 40
Laboratórios Pfizer, Lda. Tel: +351 21 423 55 00
Pfizer Croatia d.o.o. Tel: +385 1 3908 777
Pfizer România S.R.L. Tel: +40 (0)21 207 28 00
Pfizer Healthcare Ireland Tel: 1800 633 363 (toll free)
+44 (0) 1304 616161
Pfizer Luxembourg SARL
Pfizer, podružnica za svetovanje s področja farmacevtske dejavnosti, Ljubljana
Tel: +386 (0)1 52 11 400
Icepharma hf.
Sími: +354 540 8000
Pfizer Luxembourg SARL, organizačná zložka Tel: +421–2–3355 5500
Pfizer S.r.l.
Tel: +39 06 33 18 21
Pfizer Oy
Puh/Tel: +358 (0)9 430 040
Pfizer Ελλάς Α.Ε. (Cyprus Branch) Τηλ.: +357 22817690
Pfizer AB
Tel: +46 (0)8 550 520 00
Pfizer Luxembourg SARL filiāle Latvijā Tel.: + 371 670 35 775
Pfizer Limited
Tel: +44 (0)1304 616161
---------------------------------------------------------------------------------------------------------------------------
Directions for the proper use of Levetiracetam Hospira is provided in section 3.
One vial of Levetiracetam Hospira concentrate contains 500 mg levetiracetam (5 ml concentrate of 100 mg/ml). See Table 1 for the recommended preparation and administration of Levetiracetam Hospira concentrate to achieve a total daily dose of 500 mg, 1000 mg, 2000 mg, or 3000 mg in two divided doses.
Table 1. Preparation and administration of Levetiracetam Hospira concentrate
Dose | Withdrawal Volume | Volume of Diluent | Infusion Time | Frequency of administration | Total Daily Dose |
250 mg | 2.5 ml (half 5 ml vial) | 100 ml | 15 minutes | Twice daily | 500 mg/day |
500 mg | 5 ml (one 5 ml vial) | 100 ml | 15 minutes | Twice daily | 1,000 mg/day |
1,000 mg | 10 ml (two 5 ml vials) | 100 ml | 15 minutes | Twice daily | 2,000 mg/day |
1,500 mg | 15 ml (three 5 ml vials) | 100 ml | 15 minutes | Twice daily | 3,000 mg/day |
This medicinal product is for single use only, any unused solution should be discarded.
In use shelf life:
Chemical and physical in-use stability of the diluted product stored in PVC bags has been demonstrated for 24 hours at 30 °C and at 2-8 °C. From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage time and conditions are the responsibility of the user.
Levetiracetam Hospira concentrate was found to be physically compatible and chemically stable when mixed with the following diluents:
Sodium chloride 9 mg/ml (0.9%) solution for injection
Lactated Ringer’s solution for injection
Dextrose 50 mg/ml (5%) solution for injection